TP53 and non-small cell lung carcinoma: In particular, different recent studies showed that the concurrent presence of TP53 mutations negatively affects response to TKIs in EGFR-mutated NSCLC patients, suggesting a role for these gene mutations in determining primary resistance to these drugs [6,7,17,18,19,20].